GEORGE TOWN, Grand Cayman, Nov. 13, 2013 (GLOBE NEWSWIRE) -- O2Micro® International Limited (Nasdaq:OIIM), a global leader in the design, development and marketing of high-performance integrated circuits and solutions, is pleased to announce the patent grant for its Battery Module Identification methodology.
This patented methodology, issued 19 claims under United States patent number 8,525,477, assigns an address to each battery module after they have been assembled into a battery management system (BMS). Assigning unique addresses after assembly saves manufacturing time and cost.
"Self-addressing capability in the BMS lowers BMS and battery pack assembly cost, contributing toward the new energy goal for electric vehicle (EV) and/or Hybrid EV (HEV) applications," remarked Bill Densham, strategic marketing director, O2Micro.
Founded in April 1995, O2Micro develops and markets innovative power management components for the Computer, Consumer, Industrial, Automotive and Communications markets. Products include LED General Lighting, Backlighting, Battery Management and Power Management.
O2Micro International maintains an extensive portfolio of intellectual property with 24,833 patent claims granted, and over 25,000 more pending. The company maintains offices worldwide. Additional company and product information can be found on the company website at www.o2micro.com.
O2Micro, the O2Micro logo, and combinations thereof are registered trademarks of O2Micro. All other trademarks or registered trademarks are the property of their respective owners.
Statements made in this release that are not historical, including statements regarding O2Micro's or management's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. Factors that could cause actual results to differ materially include risks and uncertainties such as reduced demand for products of electronic equipment manufacturers which include O2Micro's products due to adverse economic conditions in general or specifically affecting O2Micro's markets, technical difficulties and delays in the developments process, and errors in the products. You are also referred to the Form F-1 in connection with the company's initial public offering in August 2000, Form F-3 in connection with the company's public offering in November 2001, and the annual reports on Form 20-F, which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. The company assumes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
CONTACT: Scott L. Anderson Director of Investor Relations, O2Micro Phone: 408.987.5920, x8888 Email: email@example.com
|Heatwurx Equipment Granted Patent from the U.S. Patent and Trademark Office (2013/10/21)|
|Can-Fite Granted Patent on the Manufacturing of CF101 in Japan (2014/2/25)|
|Oramed Granted Patents in Japan and Canada for its POD™ Technology for the Oral Delivery of Proteins (2013/10/3)|
|Epizyme Granted Patent Covering Diagnosis and Treatment of Cancers Associated with EZH2 Mutation (2014/4/8)|
|Oramed Granted Patent in Hong Kong for Oral Administration of Insulin (2014/4/10)|
|OncoMed Pharmaceuticals Granted Patent for Methods of Treating Cancer With Its Novel Wnt Pathway Targeting Antibody Vantictumab (OMP-18R5) (2013/8/22)|
|Tremor Video Granted Patent for Optimizing Video Advertising (2014/2/13)|
|Oramed Granted Patent in China for its Platform Technology in Oral Delivery of Proteins ()|
|Cancer Genetics, Inc. Granted Patent for Kidney Cancer Diagnosis & Typing Using a Proprietary Genomic Method ()|
|Enzymotec Ltd. Announces it has Been Granted Patents for INFAT(R)'s Uses in Canada and the US (2014/2/3)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.